High doses of biotin in chronic progressive multiple sclerosis: a pilot study

Area of Science:

• Neurology
• Biochemistry
• Clinical Research

Background:

• No current drug effectively treats progressive multiple sclerosis (MS).
• Biotin, a vitamin, is crucial for energy metabolism and myelin synthesis.
• Biotin activates acetyl-CoA carboxylase, an enzyme potentially key to myelin production.

Purpose of the Study:

• To evaluate the clinical effectiveness and safety of high-dose biotin.
• To assess biotin's impact on patients with progressive multiple sclerosis (MS).

Main Methods:

• An uncontrolled, non-blinded pilot study.
• 23 progressive MS patients received 100-300mg/day of biotin for 2-36 months.
• Clinical outcomes were assessed using quantitative and qualitative measures.

Main Results:

• Significant visual acuity improvement in 4 patients with optic nerve injury.
• 89% of patients with spinal cord involvement showed improvement.
• Neurological improvements, including visual evoked potentials and MRI markers, were observed.

Conclusions:

• Preliminary findings suggest high-dose biotin may impact progressive MS progression and disability.
• Further investigation via two ongoing double-blind placebo-controlled trials is warranted.